Pharmaceuticals and medical product regulators have urged patients who have been prescribed drugs.
If you take a typical high blood pressure drug, it is recommended that the manufacturer reports the error of the dose strength printed on some packs and then checks the drug. One placement of the lerkanidipine generated by Recota Tea Pharm is indicated by containing 10 mg tablets when it actually contains 20 mg.
According to the warning issued by the Medicine and Medical Products Regulatory Agency (MHRA), the correct dose is printed on the top and blister strips.
As a “preventive measure”, the patient must find the placement number MD4L07 as the expiration date of January 2028.
MHRA said that 7,700 packs were affected by the recall.
Those who have already prescribed the drug in this layout must call NHS 111 if they cannot immediately contact or reach GP or pharmacist.
If it is impossible to contact a medical professional, MHRA advises patients to check the strength of the tablet using information about the foil of the blister strip.
Those who have been prescribed 10 mg must take half of the 20mg tablet as a temporary solution until they consult with GP or pharmacist.
Lercanidipine is a calcium channel blocker that helps calcium prevents the heart and blood vessel muscles to reduce blood vessels and reduce blood pressure.
Excessive use in certain drugs can cause acceleration or irregular heart rate, not to mention the tendency of dizziness and sleepy feel.
Dr. Alison Cave, the chief safety officer of MHRA, emphasized: “Patient safety is our top priority. The patient asks the patient to check the pavement of the patient and follow the advice.”
Pharmacists and other medical service providers must stop distribution drugs in the affected batch and send them back to the supplier.
She also said, “Please report the suspected side effects through MHRA’s yellow card plan.”
